Tumor microenvironment-preserving gliosarcoma organoids as an in vitro preclinical platform: a comparative analysis with glioblastoma models

Abstract Background Gliosarcoma (GS) is a rare variant of glioblastoma (GBM), characterized by biphasic glial and sarcomatous histology and poor prognosis. Despite its distinct clinical features, GS remains underrepresented in glioma research due to the lack of biologically faithful and experimental...

Full description

Saved in:
Bibliographic Details
Main Authors: Junseong Park, Dokyeong Kim, Hyeon-Chun Park, Minyoung Park, Songzi Zhang, Okcho Na, Youn Soo Lee, Minho Lee, Stephen Ahn, Yeun-Jun Chung
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Journal of Translational Medicine
Subjects:
Online Access:https://doi.org/10.1186/s12967-025-06952-y
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849235058512101376
author Junseong Park
Dokyeong Kim
Hyeon-Chun Park
Minyoung Park
Songzi Zhang
Okcho Na
Youn Soo Lee
Minho Lee
Stephen Ahn
Yeun-Jun Chung
author_facet Junseong Park
Dokyeong Kim
Hyeon-Chun Park
Minyoung Park
Songzi Zhang
Okcho Na
Youn Soo Lee
Minho Lee
Stephen Ahn
Yeun-Jun Chung
author_sort Junseong Park
collection DOAJ
description Abstract Background Gliosarcoma (GS) is a rare variant of glioblastoma (GBM), characterized by biphasic glial and sarcomatous histology and poor prognosis. Despite its distinct clinical features, GS remains underrepresented in glioma research due to the lack of biologically faithful and experimentally tractable models. Methods We established patient-derived gliosarcoma organoids (GSOs) from freshly resected tumors using a suspension culture system without enzymatic dissociation. Histological, molecular, and functional properties were evaluated using H&E staining, immunohistochemistry, whole-exome sequencing, 3D invasion assays, and single-cell RNA sequencing (scRNA-seq). Drug response assays were performed using temozolomide and ANA-12 (NTRK2 inhibitor). Results GSOs preserved key histological features, genetic alterations, and tumor microenvironmental cell populations from the original tumors. They stable growth and viability over extended culture periods and maintained integrity following cryopreservation and recovery, supporting their long-term utility. 3D invasion assays further revealed infiltrative behavior, consistent with the aggressive nature of GS. Histological and molecular analyses revealed that GSOs retained glial and mesenchymal differentiation, diverse non-malignant stromal cells, and case-specific somatic alterations. Comparative scRNA-seq revealed distinct transcriptional programs: GSOs were enriched for fibroblast-like and oligodendrocyte progenitor-like states, while glioblastoma organoids (GBOs) displayed astrocyte-like differentiation and high connectivity signatures. Functional assays confirmed consistent sensitivity of GSOs to temozolomide, and selective therapeutic response to NTRK2 inhibition was observed in the GSO harboring an NTRK2 alteration, supporting the utility for genomic-context-guided therapy. Conclusion Together, GSOs constitute a tractable and translationally relevant model that faithfully reflects the cellular complexity, genetic landscape, and tumor-specific heterogeneity. This model addresses a critical gap in GS biology and supports its integration into precision oncology.
format Article
id doaj-art-27a746f94a8a4653b517a17272dcf4cf
institution Kabale University
issn 1479-5876
language English
publishDate 2025-08-01
publisher BMC
record_format Article
series Journal of Translational Medicine
spelling doaj-art-27a746f94a8a4653b517a17272dcf4cf2025-08-20T04:02:55ZengBMCJournal of Translational Medicine1479-58762025-08-0123111310.1186/s12967-025-06952-yTumor microenvironment-preserving gliosarcoma organoids as an in vitro preclinical platform: a comparative analysis with glioblastoma modelsJunseong Park0Dokyeong Kim1Hyeon-Chun Park2Minyoung Park3Songzi Zhang4Okcho Na5Youn Soo Lee6Minho Lee7Stephen Ahn8Yeun-Jun Chung9Cancer Evolution Research Center, College of Medicine, The Catholic University of KoreaPrecision Medicine Research Center, College of Medicine, The Catholic University of KoreaDepartment of Microbiology, College of Medicine, The Catholic University of KoreaDepartment of Microbiology, College of Medicine, The Catholic University of KoreaDepartment of Microbiology, College of Medicine, The Catholic University of KoreaDepartment of Microbiology, College of Medicine, The Catholic University of KoreaDepartment of Hospital Pathology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of KoreaDepartment of Life Science, Dongguk University-SeoulDepartment of Neurosurgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of KoreaPrecision Medicine Research Center, College of Medicine, The Catholic University of KoreaAbstract Background Gliosarcoma (GS) is a rare variant of glioblastoma (GBM), characterized by biphasic glial and sarcomatous histology and poor prognosis. Despite its distinct clinical features, GS remains underrepresented in glioma research due to the lack of biologically faithful and experimentally tractable models. Methods We established patient-derived gliosarcoma organoids (GSOs) from freshly resected tumors using a suspension culture system without enzymatic dissociation. Histological, molecular, and functional properties were evaluated using H&E staining, immunohistochemistry, whole-exome sequencing, 3D invasion assays, and single-cell RNA sequencing (scRNA-seq). Drug response assays were performed using temozolomide and ANA-12 (NTRK2 inhibitor). Results GSOs preserved key histological features, genetic alterations, and tumor microenvironmental cell populations from the original tumors. They stable growth and viability over extended culture periods and maintained integrity following cryopreservation and recovery, supporting their long-term utility. 3D invasion assays further revealed infiltrative behavior, consistent with the aggressive nature of GS. Histological and molecular analyses revealed that GSOs retained glial and mesenchymal differentiation, diverse non-malignant stromal cells, and case-specific somatic alterations. Comparative scRNA-seq revealed distinct transcriptional programs: GSOs were enriched for fibroblast-like and oligodendrocyte progenitor-like states, while glioblastoma organoids (GBOs) displayed astrocyte-like differentiation and high connectivity signatures. Functional assays confirmed consistent sensitivity of GSOs to temozolomide, and selective therapeutic response to NTRK2 inhibition was observed in the GSO harboring an NTRK2 alteration, supporting the utility for genomic-context-guided therapy. Conclusion Together, GSOs constitute a tractable and translationally relevant model that faithfully reflects the cellular complexity, genetic landscape, and tumor-specific heterogeneity. This model addresses a critical gap in GS biology and supports its integration into precision oncology.https://doi.org/10.1186/s12967-025-06952-yGliosarcomaPatient-derived organoidPrecision oncologySingle-cell RNA sequencingTumor microenvironment
spellingShingle Junseong Park
Dokyeong Kim
Hyeon-Chun Park
Minyoung Park
Songzi Zhang
Okcho Na
Youn Soo Lee
Minho Lee
Stephen Ahn
Yeun-Jun Chung
Tumor microenvironment-preserving gliosarcoma organoids as an in vitro preclinical platform: a comparative analysis with glioblastoma models
Journal of Translational Medicine
Gliosarcoma
Patient-derived organoid
Precision oncology
Single-cell RNA sequencing
Tumor microenvironment
title Tumor microenvironment-preserving gliosarcoma organoids as an in vitro preclinical platform: a comparative analysis with glioblastoma models
title_full Tumor microenvironment-preserving gliosarcoma organoids as an in vitro preclinical platform: a comparative analysis with glioblastoma models
title_fullStr Tumor microenvironment-preserving gliosarcoma organoids as an in vitro preclinical platform: a comparative analysis with glioblastoma models
title_full_unstemmed Tumor microenvironment-preserving gliosarcoma organoids as an in vitro preclinical platform: a comparative analysis with glioblastoma models
title_short Tumor microenvironment-preserving gliosarcoma organoids as an in vitro preclinical platform: a comparative analysis with glioblastoma models
title_sort tumor microenvironment preserving gliosarcoma organoids as an in vitro preclinical platform a comparative analysis with glioblastoma models
topic Gliosarcoma
Patient-derived organoid
Precision oncology
Single-cell RNA sequencing
Tumor microenvironment
url https://doi.org/10.1186/s12967-025-06952-y
work_keys_str_mv AT junseongpark tumormicroenvironmentpreservinggliosarcomaorganoidsasaninvitropreclinicalplatformacomparativeanalysiswithglioblastomamodels
AT dokyeongkim tumormicroenvironmentpreservinggliosarcomaorganoidsasaninvitropreclinicalplatformacomparativeanalysiswithglioblastomamodels
AT hyeonchunpark tumormicroenvironmentpreservinggliosarcomaorganoidsasaninvitropreclinicalplatformacomparativeanalysiswithglioblastomamodels
AT minyoungpark tumormicroenvironmentpreservinggliosarcomaorganoidsasaninvitropreclinicalplatformacomparativeanalysiswithglioblastomamodels
AT songzizhang tumormicroenvironmentpreservinggliosarcomaorganoidsasaninvitropreclinicalplatformacomparativeanalysiswithglioblastomamodels
AT okchona tumormicroenvironmentpreservinggliosarcomaorganoidsasaninvitropreclinicalplatformacomparativeanalysiswithglioblastomamodels
AT younsoolee tumormicroenvironmentpreservinggliosarcomaorganoidsasaninvitropreclinicalplatformacomparativeanalysiswithglioblastomamodels
AT minholee tumormicroenvironmentpreservinggliosarcomaorganoidsasaninvitropreclinicalplatformacomparativeanalysiswithglioblastomamodels
AT stephenahn tumormicroenvironmentpreservinggliosarcomaorganoidsasaninvitropreclinicalplatformacomparativeanalysiswithglioblastomamodels
AT yeunjunchung tumormicroenvironmentpreservinggliosarcomaorganoidsasaninvitropreclinicalplatformacomparativeanalysiswithglioblastomamodels